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This study was aimed to assess the clinical signiﬁcances of the serum VEGF and bFGF in Thai patients with de novo NHL. Serum
VEGF and bFGF concentrations were measured from 79 adult patients with newly diagnosed stage 2–4 non-Hodgkin lymphomas
by quantitative sandwich enzyme immunoassay. At the time of diagnosis, the serum VEGF concentrations from 79 patients
ranged from 72.0 to 2919.4pg/mL, with a mean of 668.0pg/dL. The serum bFGF concentrations ranged from undetectable to
2919.4pg/mL, with a mean of 12.15pg/dL. Multivariate analysis identiﬁed higher than the mean of serum VEGF, B symptoms,
bulky diseases, anemia, and treatment with CHOP or R-CHOP as independent variables inﬂuencing the complete remission rate.
From a Cox proportional hazards model, variables independently associated with overall survival were bone marrow involvement,
more extranodal involvement, poor performance status, anemia, and higher than the mean of serum bFGF.
1.Introduction
Angiogenesis, the formation of new blood vessels, is of
great importance in neoplastic growth and progression in
both solid and hematologic malignancies. The growing of
new capillaries is activated by proangiogenic molecules such
as vascular endothelial growth factor (VEGF) and basic
ﬁbroblast growth factor (bFGF). The VEGF is a soluble 46-
kD protein and the bFGF is an 18- to 24-kD polypeptide [1–
3]. In solid tumors, the progenetic molecules act as inducers
of neovascularization, thereby enhancing tumor growth and
metastatic potential [4].
In hematologic malignancies, roles of angiogenesis were
established in multiple myeloma (MM). Various studies had
shown that increased microvascular density in bone marrow
was associated with poor prognosis [5, 6]. Importantly,
yet other studies found that antiangiogenic agents such as
thalidomide or immunomodulatory drugs were associated
with survival advantages in patients with MM [7–9].
Though predictive values of serum angiogenic factors in
non-Hodgkin lymphoma (NHL) have been studied, conﬁr-
mation studies in diﬀerent ethnic groups should be con-
ducted. Therefore, this study was undertaken to assess the
clinical signiﬁcance of the serum proangiogenic molecules,
VEGF, and bFGF, in Thai patients with de novo NHL.
2.MaterialsandMethods
A total of 79 adult patients with newly diagnosed stage 2–4
non-Hodgkin lymphomas was enrolled at Songklanagarind
Hospital,themajortertiarycarecenterinsouthernThailand,
between December 30, 2005 and April 9, 2009. Patients
with a reactive test for human immunodeﬁciency virus or
primary extranodal lymphomas were excluded. Histological
classiﬁcation was in accordance with the WHO classiﬁcation
system. Monoclonal antibodies targeting CD3, CD5, CD20,
and CD79a (Dako, Glostrup, Denmark) were used for the T-
or B-lineage determination. This study was approved by the
Ethics Committee of Prince of Songkla University.
Clinical staging was evaluated according to the Ann
Arbor staging system. Prognostic assessment was performed
based on the International Prognostic Index (IPI).
All patients were treated with a standard CHOP regimen
including a minimum of six courses of cyclophosphamide,
doxorubicin, vincristine, and prednisolone. Rituximab was2 The Scientiﬁc World Journal
Table 1: Initial characteristics of 79 patients with de novo NHL.
Characteristic No (%)
Performance status (ECOG ≥2) 15 (19.0)
B symptoms 46 (58.2)
Ann Arbor stage
I7 ( 8 . 9 )
II 22 (27.8)
III 10 (12.7)
IV 40 (50.6)
Bulky disease 28 (35.4)
Bone marrow involvement 26 (32.9)
High serum LDH 46 (58.2)
Histological subtype
Diﬀuse large cell lymphoma 54 (68.4)
Follicular lymphoma 8 (10.1)
Mantle cell lymphoma 3 (3.8)
Lymphoblastic lymphoma 2 (2.5)
Burkitt’s lymphoma 1 (1.3)
Mucosa-associated lymphoid tissue 1 (1.3)
Peripheral T-cell lymphoma, unclassiﬁed 6 (7.6)
Anaplastic large cell lymphoma 3 (3.8)
Angioimmunoblastic T-cell lymphoma 1 (1.3)
International prognostic index
Low risk 24 (30.4)
Low-intermediate risk 20 (25.3)
High-intermediate risk 21 (26.6)
High risk 14 (17.7)
Chemotherapy
CHOP 44 (55.7)
R-CHOP 22 (27.8)
Other 7 (8.9)
No chemotherapy 6 (7.6)
not routinely administered in Thailand. Treatment response
was classiﬁed as complete remission (CR), undetermined
complete remission (CRu), partial remission (PR), stable
disease (SD), or progressive disease (PD) according to the
standard criteria.
TenmLofperipheralvenousbloodsampleswascollected
from all participants before their treatment was begun. All
samples were centrifuged at 2000g for 10 minutes and frozen
at −20◦C soon after collection. The samples were thawed
and analysed after 12–24 months’ storage. Serum VEGF and
bFGF concentrations were measured by quantitative sand-
wich enzyme immunoassay technique (Quantikine R; R&D
systems, Minneapolis, MN) following the manufacturers’
instructions. All analyses and calibrations were performed
in duplicate. A set of standard wells containing known
quantities of recombinant human VEGF and bFGF were
included in all experiments. Concentrations were recorded
as the mean of duplicate measurements in picograms per
milliliter.Theintra-andinterassayvariationswerewithinthe
ranges given by the manufacturers.
2.1. Statistical Analysis. Frequency tables of baseline char-
acteristics were analyzed with the Chi-square or Fisher’s
exact test. A logistic regression model was used to predict
complete remission (CR). Univariate analysis of survival was
performed with the Kaplan-Meier method. Overall survival
(OS) was calculated as the time interval from the date of
diagnosis to death or last followup. Kaplan-Meier methods
were used to estimate time-to-event endpoints. Survival
data between subgroups were compared using the log rank
test. Multivariate analysis of OS was performed using a
Cox regression model with backward elimination. Critical P
values for entry and removal were 0.2 and 0.4, respectively.
To test the main hypothesis, we forced the serum level of
VEGF and bFGF into the model. Hazard ratios (HR), 95%
conﬁdence intervals (95% CI), and P value were obtained
from the best-ﬁt model. All the statistical analyses were
performed using the R program with epicalc package. A
signiﬁcance level of 0.05 was used throughout all statistical
tests in the study.
3. Results
3.1. Patient Characteristics and Histological Subtypes. The
clinicalcharacteristicsofthe79patientsareshowninTable 1.
There were 38 males and 41 females with a mean age of 55.2
(range 16–82) years. Regarding immunohistochemistry, the
B-cell phenotype was shown in 69 specimens (87.3%), and
10 tissue specimens (12.7%) expressed the T-cell phenotype.
3.2. Serum VEGF and bFGF at the Time of Diagnosis. At the
time of diagnosis, the serum VEGF concentrations from the
79 patients ranged from 72.0 to 2919.4pg/mL with a mean
of668.0pg/dL,medianof516.0pg/mL,andthethirdquartile
of 835.5pg/mL. The serum bFGF concentration ranged from
undetectable to 2919.4pg/mL with a mean of 12.15pg/dL,
median of 9.85pg/mL, and third quartile of 17.60pg/mL.
Associations between serum VEGF and bFGF and clinical
features at diagnosis were analyzed using mean, median,
and the third quartile of both angiogenetic factors as a cut-
oﬀ value. No signiﬁcant associations were found (data not
shown).
3.3. Prediction of Response Rate by Serum VEGF and bFGF.
From a univariate analyses, the higher levels of serum VEGF
and bFGF using the mean, median, and third quartile
of both angiogenetic factors as cut-oﬀ values were not
associated with a poorer complete remission (CR) rate.
However, patients with B symptoms, bulky diseases, ane-
mia, poorer performance status, high serum LDH, and T-
cell immunophenotype had lower CR rates. Considering
the chemotherapy regimens, CHOP and R-CHOP showed
higher CR rates. Multivariate analysis identiﬁed higher than
the mean of serum VEGF, B symptoms, bulky diseases, ane-
mia, and treatment with CHOP or R-CHOP as independent
variables inﬂuencing CR rate (Table 2).
3.4. Prediction of Survival Rate by Serum VEGF and bFGF.
The median follow-up time was 15.1 (range 0.3–55.2)The Scientiﬁc World Journal 3
Table 2: Univariate and multivariate analysis for complete response and overall survival.
Complete response Overall survival
Variable Univariate OR (95%
CI)#
Multivariate OR (95%
CI)#
Univariate HR (95%
CI)#
Multivariate HR
(95% CI)#
Age: ≥60 years 1.34 (0.52, 3.45) Not tested 1.31 (0.68, 2.54) Not tested
Sex: female 0.94 (0.37, 2.39) Not tested 1.21 (0.62, 2.33) Not tested
B symptoms 10.29 (3.05, 34.71)∗∗∗ 10.6 (1.79, 62.65)∗∗ 3.20 (1.53, 6.71)∗∗ Not tested
Bulky diseases 2.95 (1.1, 7.88)∗ 5.32 (1, 28.23)∗ 0.84 (0.42, 1.68) Not tested
Stage: III-IV 2.1 (0.77, 5.73) Not in ﬁnal model 1.94 (0.93, 4.05) Not in ﬁnal model
BM involvement 1.89 (0.69, 5.2) Not in ﬁnal model 1.54 (0.79, 3.0) 0.30 (0.11, 0.82)∗
Liver involvement 1.27 (0.41, 3.91) Not tested 1.50 (0.74, 3.01) Not in ﬁnal model
Extranodal involvement: >2 2.09 (0.57, 7.6) Not in ﬁnal model 2.47 (1.19, 5.14)∗ 2.60 (1.03, 6.51)∗
Performance status: ECOG
2–4 6.3 (1.54, 25.83)∗ Not in ﬁnal model 4.37 (2.12, 8.98)∗∗∗ 4.44 (1.84, 10.72)∗∗∗
High serum LDH 3.43 (1.22, 9.67)∗ Not in ﬁnal model 3.85 (1.67, 8.89)∗∗ 1.53 (0.53, 4.46)
IHC: T-cell 4.45 (1.05, 18.94)∗ Not in ﬁnal model 2.22 (0.92, 5.36) Not in ﬁnal model
Anemia 6.31 (2.14, 18.63)∗∗∗ 10.9 (1.63, 73)∗∗ 3.92 (1.83, 8.42)∗∗∗ 4.14 (1.40, 12.26)∗
Lymphopenia 2.18 (0.8, 5.96) Not in ﬁnal model 1.80 (0.90, 3.57) 2.25 (1.00, 5.07)∗
IPI: HI-high 1.94 (0.53, 7.13) Not in ﬁnal model 3.24 (1.60, 6.53)∗∗ Not tested
Chemotherapy:
CHOP 0.25 (0.05, 1.4)∗ 0.2 (0.02, 2.42)∗∗∗ 0.41 (0.18, 0.90)∗ 0.13 (0.04, 0.41)∗∗∗
R-CHOP 0.07 (0.01, 0.51) 0.01 (0, 0.26) 0.24 (0.09, 0.64)∗∗ 0.04 (0.01, 0.19)∗∗∗
Serum VEGF (pg/mL)
>668.0 (mean) 2 (0.75, 5.3) 5.33 (0.97, 29.27)∗ 1.37 (0.71, 2.64) Not in ﬁnal model
>516.0 (median) 2.12 (0.82, 5.49) Not tested 0.99 (0.51, 1.90) Not tested
>835.5 (3rd Qu) 1.76 (0.58, 5.38) Not tested 1.03 (0.48, 2.18) Not tested
Serum bFGF (pg/mL)
>12.15 (mean) 1.19 (0.44, 3.23) 1.68 (0.37, 7.71) 2.08 (1.07, 4.03)∗ 3.31 (1.32, 8.30)∗
>9.85 (median) 1.86 (0.69, 4.98) Not tested 1.75 (0.90, 3.42) Not tested
>17.60 (3rd Qu) 1.24 (0.4, 3.87) Not tested 1.96 (0.97, 3.94) Not tested
#Signiﬁcance level: ∗∗∗0.001, ∗∗0.01, ∗0.05.
months. In univariate survival analyses, there was no asso-
ciation between serum VEGF and OS (Figure 1(a)).
However, there was a signiﬁcant association between
shorter OS and B symptoms, more extranodal involve-
ments, poor performance status, anemia, high serum LDH,
bFGF (Figure 1(b)), and IPI. In contrast, the CHOP or
R-CHOP regimens were predictors for better OS. From a
Cox proportional hazards model, variables independently
associated with OS were BM involvement, more extranodal
involvement, poor performance status, anemia, and higher
than the mean of serum bFGF as shown in Table 2.
4. Discussion
In this study, a high pretreatment level of serum VEGF and
bFGF were independently associated with poorer CR and OS
rates, respectively. Although the role of neovascularization
in hematologic malignancies has been extensively explored,
few studies have been conducted on the role of angiogenesis
in lymphomas [10]. In addition, the predictive value of
angiogenesis markers in lymphomas is still controversial
due to disease heterogeneity and various detection methods
[11]. However, serum proangiogenetic markers are a simple
methodandhavetheconsiderableadvantageofnotrequiring
anexperiencedpathologisttoreliablyassess.Therehavebeen
only a few published studies on these serum proangiogenetic
markers in clinical settings. However, confounding variables
of known clinical prognostic factors were not considered in
some of these reports. Therefore, we conducted this study
to determine the independent association between these
markers and clinical outcomes.
In earlier studies, Salven et al. [12–14] and Bertolini et al.
[15] demonstrated a signiﬁcant association between these
markers and the outcomes of patients with NHL in concor-
dance with our study. The correlation between high VEGF
levels and poor CR rate also supported the hypothesis that
high VEGF is responsible for an abnormal vessel structure
of tumors leading to lowering drug delivery [4]. However,
o u rm o r er e c e n ts t u d yf o u n dh i g h e rl e v e l so fp r e t r e a t m e n t
VEGF and bFGF, probably because the patients in our study
had more advanced stages of disease. Ribatti et al. [16]a n d
Crivellato et al. [17] also found that neovascularization was4 The Scientiﬁc World Journal
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Figure 1: (a) Overall survival by mean VEGF (b) Overall survival by mean bFGF.
found frequently in high-grade lymphoma. The diﬀerent
serum VEGF and bFGF levels before treatment in patients
with diﬀerent degrees of disease, or due to other factors,
may lead to diﬃculty in obtaining a single cut-oﬀ value
for a predictor in all patients with NHL. In addition, the
level of bFGF may be elevated due to other conditions
associated with increased endothelial activity, infection, or
inﬂammation [18, 19].
Importance roles of angiogenesis in lymphomas have
been demonstrated in clinical studies. Tzankov and col-
leagues [20] performed immunohistochemical and mor-
phometric studies in B-cell lymphomas and found higher
microvessel density, and VEGF and COX2 in aggressive
lymphomas. This result is in concordance with Ganjoo et
al. [21] who reported that patients with negative stained
VEGF-A or VEGF-R1 had a superior survival rate. These
studies conﬁrmed the potential importance of increased
angiogenesisinprognosisandtrackingofdiseaseprogression
in non-Hodgkin lymphomas.
In conclusion, our study suggests that serum VEGF
and bFGF are associated with poor prognosis in patients
with de novo non-Hodgkin lymphomas. Further studies
are needed to determine more clearly whether monitoring
of consecutive levels of these molecules during or after
therapy could predict CR or relapse. In addition, these
markers may play an important role in patient selection for
antiangiogenetic treatment.
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